Lenvatinib Plus Pembrolizumab vs Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
J. Clin. Oncol 2024 Jan 16;[EPub Ahead of Print], RJ Motzer, C Porta, M Eto, T Powles, V Grünwald, TE Hutson, B Alekseev, SY Rha, J Merchan, JC Goh, AA Lalani, U De Giorgi, B Melichar, SH Hong, H Gurney, MJ Méndez-Vidal, E Kopyltsov, S Tjulandin, TA Gordoa, V Kozlov, A Alyasova, E Winquist, P Maroto, M Kim, A Peer, G Procopio, T Takagi, S Wong, J Bedke, M Schmidinger, K Rodriguez-Lopez, J Burgents, C He, CE Okpara, J McKenzie, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.